Clinical Trials · NCT02427958
A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese Participants
- Phase
- Phase 4
- Recruitment status
- Completed
- Sponsor
- Takeda
- Enrollment
- 307
- Start date
- Aug 2015
- Locations
- 9 sites, China
- Primary endpoint
- Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)